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The primary objective of our current HIV vaccine research
program is to evaluate novel alphavirus-based and Enve-
lope (Env) protein-based vaccine formulations either
alone or in prime boost regimen for improved immuno-
genicity and efficacy over other HIV vaccine approaches.
The outcome of this work will be the production of candi-
date vaccine components that can be further advanced to
clinical trials in human subjects. For these studies we
employ viral genes derived from SF162 a primary subtype
B HIV-1 isolate in alphavirus replicon particle-based vac-
cines. A chimeric alphavirus vector system (VEE/SIN) is
used that is composed of the Venezuelan Equine Encepha-
litis (VEE) replicon combined with the Sindbis virus struc-
tural proteins. We have performed a proof of concept
study where macaques were primed with VEE/SIN,
boosted with o-gp140DV2SF162, and challenged intrave-
nously by pathogenic SHIVSF162P4. In the next study we
evaluated these recombinant VEE/SIN vaccines alone, and
also in combination with DV2-trimer derived from SF162
for their ability to protect against mucosal SHIVSF162P4
challenge. Both parenteral and mucosal routes of immu-
nization have been evaluated to identify the optimal regi-
men(s) for the induction of potent and protective
humoral and cellular responses in rhesus macaques. In
the third study, we evaluated the ability of DV2SF162
trimer to protect against against mucosal SHIVSF162P4
challenge. Both parenteral and mucosal routes of immu-
nization have been evaluated. Results so far indicate that
the recombinant VEE/SIN particles induced antigen-spe-
cific CD4+ and CD8+ T cell responses as well as neutraliz-
ing antibodies in small animals (mice and rabbits) and
non-human primates. Moreover, intramuscular immuni-
zation with VEE/SIN particles encoding SIV gag or gagpol
and HIV env is quite effective in priming for potent anti-
Env antibody responses. However, it seems intramuscular
boosting of alpha primed animals with o-
gp140DV2SF162 in MF59 is critical for blocking and/or
reducing acute phase viremia following either intravenous
or intrarectal SHIVSF162P4 challenges of rhesus
macaques. Furthermore, macaques that were immunized
intranasally with o-gp140DV2SF162 protein in the LTK63
mucosal adjuvant followed by intramuscular immuniza-
tion with o-gp140DV2SF162 in MF59 were also protected
against SHIVSF162P4 challenge. Protection in these stud-
ies appears to occur after the induction of high titer serum
neutralizing antibodies that recognize the challenge virus.
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